The Moving Mountains for Multiple Myeloma Machu Picchu Full Documentary

Research demonstrated comparable outcomes in the real-world setting and in the phase 2 MajesTEC-1 trial when it came to treatment with Tecvayli for relapsed or refractory myeloma.

From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.

An expert discusses the FDA’s investigation into the possible association between CAR-T cell therapy and secondary T-cell malignancies.

In this episode of the “Cancer Horizons” podcast, a physician assistant recalls his experience as a frontline health care worker during the COVID-19 pandemic and what it was like to get diagnosed with multiple myeloma during such a chaotic time.

I found family in my cancer support groups.